• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Venturefest Bristol 2011, John Clarkson,
 

Venturefest Bristol 2011, John Clarkson,

on

  • 334 views

 

Statistics

Views

Total Views
334
Views on SlideShare
334
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Venturefest Bristol 2011, John Clarkson, Venturefest Bristol 2011, John Clarkson, Presentation Transcript

    • John Clarkson, CEOVenturefest, Bristol 2011Contact:john.clarkson@atlasgenetics.com
    • Seed Series A Interim Series BFunds £1 m £2 m £0.5 m £18.5 mDate 2005 2007 2009 2011Milestones Product Prototype Clinical validation Transfer to concept development manufacture, Product launch and menu expansion
    •  Seed ◦ University of Bath, YFM, private investors (SWAIN) Series A ◦ YFM, Braveheart, private investors Interim ◦ YFM, private investors Series B ◦ Novartis Venture Funds, J&J Development Corp, LSP, BB Biotech, Consort Medical plc, private investors
    •  Seed ◦ Ordinary (EIS qualifying) Series A ◦ Investor (EIS Qualifying plus exit pref) & Pref Interim ◦ Investor & Pref Series B ◦ Investor and Series B Pref
    •  Most rapidly growing segment of the diagnostics market Experienced management team and board ◦ Diagnostics industry experience: J&J, Siemens, Osmetech, Axis Shield ◦ Successful delivery of similar projects: product launch, licensing, trade sale Major problems being addressed ◦ slow speed of diagnosis; falling GP revenues Significant product benefits, well protected IP Convincing and demonstrable milestones completed – external clinical validation at JHU £1.6m TSB grant for core product development Raising £2m for end 2010
    •  Approached European and US VCs during Q1 & Q2 2010 ◦ European: interest. Good contacts through IN3 Europe. Funding insufficient to take the company to product launch in US – raise more ◦ US: no interest: too little money, too far away
    •  Approached European and US VCs during Q1 & Q2 2010 ◦ European: interest. Good contacts through IN3 Europe. Funding insufficient to take the company to product launch in US – raise more ◦ US: no interest: too little money, too far away Approached diagnostic/medical companies: OCD (J&J), Novartis Vaccines & Diagnostics and approached by Consort Medical from July 2010 ◦ Interested, particularly Consort Medical
    •  Approached European and US VCs during Q1 & Q2 2010 ◦ European: interest. Good contacts through IN3 Europe. Funding insufficient to take the company to product launch in US – raise more ◦ US: no interest: too little money, too far away Approached diagnostic/medical companies: OCD (J&J), Novartis Vaccines & Diagnostics and approached by Consort Medical from July 2010 ◦ Interested, particularly Consort Medical Contacted by Novartis Venture Funds (NVF) and J&J DC in August/September 2010
    •  Approached European and US VCs during Q1 & Q2 2010 ◦ European: interest. Good contacts through IN3 Europe. Funding insufficient to take the company to product launch in US – raise more ◦ US: no interest: too little money, too far away Approached diagnostic/medical companies: OCD (J&J), Novartis Vaccines & Diagnostics and approached by Consort Medical from July 2010 ◦ Interested, particularly Consort Medical Contacted by Novartis Venture Funds (NVF) and J&J DC in August/September 2010 Term sheet with NVF in December 2011; Used JP Morgan meeting to build syndicate. J&J DC joined Feb 2011; completed July 2011
    •  Changed business plan: more dilution ◦ £18.5m vs. £2m – bigger, better and more realistic plan. Less financial risk, exceptionally strong syndicate = better exit
    •  Changed business plan: more dilution ◦ £18.5m vs. £2m – bigger, better and more realistic plan. Less financial risk, exceptionally strong syndicate = better exit Series B prefs dominate ◦ Negotiated better terms for Ordinary shares
    •  Changed business plan: more dilution ◦ £18.5m vs. £2m – bigger, better and more realistic plan. Less financial risk, exceptionally strong syndicate = better exit Series B prefs dominate ◦ Negotiated better terms for Ordinary shares One early investors wanted to exit ◦ Negotiated share sale to series B investors
    •  Network ◦ Cold call will never work, but investor conferences might; better to be introduced by a trusted intermediate Power point Business plan: short and sweet. ◦ Management, market, product, finance Get a meeting Make the investors comfortable with the team Find a contact you can contact ◦ Someone who will feel guilty if they don’t respond Persist ◦ And find someone you can complain to